Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.56 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627527 | 0.89 | PDE4B (0.62) | PDE4BCSF1R | |
| SCHEMBL4627633 | 0.87 | SYK (0.49) | PDE4BSYKCSF1R | |
| SCHEMBL4627622 | 0.84 | PDE4B (0.73) | PDE4BCSF1R | |
| SCHEMBL4625981 | 0.81 | PDE4B (0.59) | PDE4BCSF1R | |
| SCHEMBL4626888 | 0.81 | PDE4B (0.60) | PDE4BCSF1R | |
| SCHEMBL4627505 | 0.81 | PDE4B (0.60) | PDE4BCSF1R | |
| SCHEMBL4656275 | 0.79 | SLC2A1 (0.48) | PDE4B | |
| SCHEMBL4625955 | 0.79 | PDE4B (0.73) | PDE4BCSF1R | |
| SCHEMBL5401565 | 0.78 | PDE4B (0.58) | PDE4BCSF1R | |
| SCHEMBL4628792 | 0.76 | PDE4B (0.57) | PDE4BSYKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | claimed |
| EP-1673086-B1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2008-01-23 | — | — | EP | claimed |
| JP-2007506703-A | — | — | 2007-03-22 | — | — | JP | claimed |
| EP-1673086-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | claimed |
| WO-2005030212-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | claimed |
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | US | disclosed |
| EP-1673086-B1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1673086-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030212-A1 | 4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096884-A1 | 4-Aminoquinoline-3-Carboxamide Derivatives as Pde4 Inhibitors | PDE4A, PDE4B, PDE3B | PDE4B 2/4885SYK 1833/4885CSF1R 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.